Brain Endothelial Cell Receptor for Escherichia coli

大肠杆菌脑内皮细胞受体

基本信息

  • 批准号:
    8689878
  • 负责人:
  • 金额:
    $ 44.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-01-01 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Escherichia coli K1 is the most common cause of meningitis in neonates. Ineffectiveness of antibiotic therapy over the last few decades and the emergence of antibiotic resistant E. coli strains imply that there is a great unmet need for new methods of treatment and prevention. Incomplete understanding of the mechanisms involved at every step of pathogenesis is attributed to this poor outcome. For example, the mechanisms by which E. coli K1 enters the human brain microvascular endothelial cells (HBMEC) that constitute the BBB and disrupts tight junctions (TJs) are poorly understood. We have established that outer membrane protein A (OmpA) of E. coli interacts with endothelial cell gp96 (Ecgp); a receptor specifically expressed on HBMEC, to invade and disrupt the TJs. The importance of OmpA-Ecgp interaction is further supported by our findings that 1) E. coli strains that either lack OmpA or express non-functional OmpA do not induce meningitis in a newborn mouse or rat model and 2) Mice in which Ecgp expression was suppressed were resistant to E. coli infection. Intriguingly, OmpA interaction with Ecgp triggers the production of nitric oxide (NO) due to iNOS activation and thereby enhances the expression of the receptor to allow the bacteria to invade more efficiently. In agreement, iNOS-/- mice are resistant to E. coli infection and also administration of an iNOS specific inhibitor, aminoguanidine (AG), during high-grade bacteremia prevented the occurrence of meningitis. Novel computer modeling methods were utilized to study the interaction of OmpA and Ecgp and to identify small molecule inhibitors that prevent the E. coli invasion of HBMEC. Three small molecules exhibited more than 80% inhibition of E. coli invasion in HBMEC both in vitro and in vivo. Our studies have also revealed that Ecgp interaction with Robo4 at the HBMEC membrane increases upon infection with E. coli. Further, a GTPase activating protein, IQGAP1, which binds both actin and b-catenin, appears to play a role in the invasion process. IQGAP1 is a client protein for Stat3, which was shown to be associated with Ecgp, indicating that IQGAP1 might be relaying Ecgp mediated signals to induce E. coli invasion. Thus, our hypothesis is that the interaction of OmpA and Ecgp is fundamental to initiate signaling events that induce E. coli invasion and increased permeability of the BBB. In Aim 1, we propose to define the binding domains of Ecgp that orchestrate the interaction of Ecgp/Robo4 with OmpA. Next, to understand whether Ecgp interaction with Robo4 contributes to signaling events to induce NO production and thereby modulating IQGAP1 association with b-CAT to dislodge it from TJs will be tested in Aim 2. Then, in Aim 3 we will modify the antagonists for higher inhibition efficiency and couple them to nanoparticles, which will carry a load of iNOS inhibitors to deliver to brain to prevent E. coli induced meningitis in newborn rats. Translational medicine is the outcome of this application in which studies of basic biology and applied technology to develop new strategies of prevention will be integrated.
描述(由申请方提供):大肠埃希菌K1是新生儿脑膜炎的最常见病因。过去几十年来抗生素治疗的无效和耐药大肠杆菌的出现。大肠杆菌菌株的感染意味着对新的治疗和预防方法存在巨大的未满足的需求。对发病机制的每一步的不完全理解是导致这种不良结局的原因。例如,E. coli K1进入人脑微血管内皮细胞(HBMEC)并破坏紧密连接(TJ)的机制尚不清楚。我们已经确定了E.大肠杆菌与内皮细胞gp 96(Ecgp)相互作用,侵入并破坏TJ; OmpA-Ecgp相互作用的重要性进一步得到以下结果的支持:1)E.缺乏OmpA或表达非功能性OmpA的大肠杆菌菌株在新生小鼠或大鼠模型中不诱导脑膜炎;大肠杆菌感染。有趣的是,OmpA与Ecgp的相互作用由于iNOS活化而触发一氧化氮(NO)的产生,从而增强受体的表达,使细菌更有效地侵入。与此一致,iNOS-/-小鼠对E.大肠杆菌感染,也管理的iNOS特异性抑制剂,氨基胍(AG),在高级别菌血症预防脑膜炎的发生。利用计算机模拟方法研究OmpA和Ecgp的相互作用,并筛选出抑制E.大肠杆菌侵袭HBMEC。三种小分子对大肠杆菌的抑制率均在80%以上。大肠杆菌在HBMEC中的侵袭能力。我们的研究还表明,当感染E.杆菌此外,GT3活化蛋白IQGAP 1结合肌动蛋白和β-连环蛋白,似乎在侵袭过程中发挥作用。IQGAP 1是Stat 3的客户蛋白,Stat 3被证明与Ecgp相关,表明IQGAP 1可能中继Ecgp介导的信号以诱导E.大肠杆菌侵袭。因此,我们的假设是OmpA和Ecgp的相互作用是启动诱导E.大肠杆菌侵袭和血脑屏障通透性增加。在目的1中,我们提出定义的结合域的Ecgp编排的相互作用的Ecgp/Robo 4与OmpA。接下来,为了理解Ecgp与Robo 4的相互作用是否有助于诱导NO产生的信号传导事件,从而调节IQGAP 1与b-CAT的结合以将其从TJ中驱逐,将在目标2中进行测试。然后,在目标3中,我们将修饰拮抗剂以获得更高的抑制效率,并将其偶联到纳米颗粒上,纳米颗粒将携带iNOS抑制剂负载到大脑中以防止E。coli诱导的新生大鼠脑膜炎。转化医学是这种应用的结果,其中基础生物学和应用技术的研究,以开发新的预防策略将被整合。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK E DAVIS其他文献

MARK E DAVIS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK E DAVIS', 18)}}的其他基金

Project 1: Targeted Nanoparticle Therapeutics for Treating Intracranial Disease
项目1:靶向纳米粒子治疗颅内疾病
  • 批准号:
    8962030
  • 财政年份:
    2015
  • 资助金额:
    $ 44.78万
  • 项目类别:
A Novel Method of Nanoparticle Delivery to Brain by Targeting Ec-gp96
一种靶向 Ec-gp96 的纳米粒子递送至大脑的新方法
  • 批准号:
    8078838
  • 财政年份:
    2010
  • 资助金额:
    $ 44.78万
  • 项目类别:
In Vivo Pharmacodynamics of RNAi-based Cancer Therapies
基于 RNAi 的癌症疗法的体内药效学
  • 批准号:
    7983569
  • 财政年份:
    2010
  • 资助金额:
    $ 44.78万
  • 项目类别:
A Novel Method of Nanoparticle Delivery to Brain by Targeting Ec-gp96
一种靶向 Ec-gp96 的纳米粒子递送至大脑的新方法
  • 批准号:
    8246434
  • 财政年份:
    2010
  • 资助金额:
    $ 44.78万
  • 项目类别:
A Novel Method of Nanoparticle Delivery to Brain by Targeting Ec-gp96
一种靶向 Ec-gp96 的纳米粒子递送至大脑的新方法
  • 批准号:
    7949884
  • 财政年份:
    2010
  • 资助金额:
    $ 44.78万
  • 项目类别:
Design of Gene Delivery System to Target Hepatocytes
靶向肝细胞的基因递送系统的设计
  • 批准号:
    7347036
  • 财政年份:
    2005
  • 资助金额:
    $ 44.78万
  • 项目类别:
Design of Gene Delivery System to Target Hepatocytes
靶向肝细胞的基因递送系统的设计
  • 批准号:
    7011210
  • 财政年份:
    2005
  • 资助金额:
    $ 44.78万
  • 项目类别:
Design of Gene Delivery System to Target Hepatocytes
靶向肝细胞的基因递送系统的设计
  • 批准号:
    7172284
  • 财政年份:
    2005
  • 资助金额:
    $ 44.78万
  • 项目类别:
Design of Gene Delivery System to Target Hepatocytes
靶向肝细胞的基因递送系统的设计
  • 批准号:
    6862243
  • 财政年份:
    2005
  • 资助金额:
    $ 44.78万
  • 项目类别:
Brain Endothelial Cell Receptor for Escherichia coli
大肠杆菌脑内皮细胞受体
  • 批准号:
    8291201
  • 财政年份:
    1997
  • 资助金额:
    $ 44.78万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 44.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 44.78万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 44.78万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 44.78万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 44.78万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 44.78万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 44.78万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 44.78万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 44.78万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 44.78万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了